A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Nature Communications

Volumn 7, Issue , 2016, Pages

  Ferrari, Anthony ^a   Vincent Salomon, Anne ^b   Pivot, Xavier ^c   Sertier, Anne Sophie ^a   Thomas, Emilie ^a   Tonon, Laurie ^a   Boyault, Sandrine ^a   Mulugeta, Eskeatnaf ^b   Treilleux, Isabelle ^a   MacGrogan, Gaëtan ^d   Arnould, Laurent ^e   Kielbassa, Janice ^a   Le Texier, Vincent ^a   Blanché, Hélène ^f   Deleuze, Jean François ^f   Jacquemier, Jocelyne ^g   Mathieu, Marie Christine ^h   Penault Llorca, Frédérique ⁱ   Bibeau, Frédéric ^j   Mariani, Odette ^b   Mannina, Cécile ^d   Pierga, Jean Yves ^b   Trédan, Olivier ^a   Bachelot, Thomas ^a   Bonnefoi, Hervé ^k   Romieu, Gilles ^j   Fumoleau, Pierre ^e   Delaloge, Suzette ^h   Rios, Maria ^l   Ferrero, Jean Marc ^m   Tarpin, Carole ^g   Bouteille, Catherine ⁿ   Calvo, Fabien ^h   Gut, Ivo Glynne ^o,p   Gut, Marta ^o,p   Martin, Sancha ^q   Nik Zainal, Serena ^q,r   Stratton, Michael R ^q   Pauporté, Iris ^s   Saintigny, Pierre ^a,t,u   Birnbaum, Daniel ^v   Viari, Alain ^a,w   Thomas, Gilles ^a   more..

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d INSTITUT BERGONIÉ   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f FONDATION JEAN DAUSSET CEPH   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ CENTRE JEAN PERRIN   (France)

^j CENTRE VAL D AURELLE   (France)

^k UNIVERSITÉ DE BORDEAUX   (France)

^l CENTRE ALEXIS VAUTRIN   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

ⁿ Clinique Mutualiste   (France)

^o CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^p UNIVERSITAT POMPEU FABRA   (Spain)

^q WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^r CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^s INSTITUT NATIONAL DU CANCER   (France)

^t CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^u UNIVERSITÉ DE LYON   (France)

^v AIX MARSEILLE UNIVERSITY   (France)

^w INRIA   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; RNA; TRANSCRIPTOME; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; PROGESTERONE RECEPTOR;

CANCER; DISEASE SEVERITY; DISEASE TREATMENT; GENE EXPRESSION; GENETIC ANALYSIS; GENOME; MUTATION;

ADULT; AMPLICON; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COPY NUMBER VARIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN GENOME; HUMAN TISSUE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SOMATIC MUTATION; BREAST TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE GENOME SEQUENCING;

BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TRANSCRIPTOME; WHOLE GENOME SEQUENCING;

EID: 84978795367     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12222     Document Type: Article

References (69)

1. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
2. Prat, A. et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J. Natl Cancer Inst. 106, dju152 (2014).
3. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
4. Marty, M. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23, 4265-4274 (2005).
5. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
6. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
7. Piccart-Gebhart, M. et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase iii adjuvant lapatinib and/or trastuzumab treatment optimization trial. J. Clin. Oncol. 34, 1034-1042 (2014).
8. von Minckwitz, G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796-1804 (2012).
9. Denkert, C. et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. 15, R11 (2013).
10. Cortazar, P. et al. Pathological complete response and long-term clinicalbenefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164-172 (2014).
11. Carey, L. A. et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J. Clin. Oncol. 34, 542-549 (2015).
12. Esteva, F. J. et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 177, 1647-1656 (2010).
13. Jensen, J. D. et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann. Oncol. 23, 2034-2042 (2012).
14. Baselga, J. et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J. Clin. Oncol. 32, 3753-3761 (2014).
15. Loibl, S. et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J. Clin. Oncol. 32, 3212-3220 (2014).
16. Majewski, I. J. et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J. Clin. Oncol. 33, 1334-1339 (2015).
17. Rody, A. et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 11, R15 (2009).
18. Bianchini, G. et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann. Oncol. 26, 2429-2436 (2015).
19. Pivot, X., Romieu, G., Debled, M., Pierga, J.-Y. & Kerbrat, P. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 14, 741-748 (2013).
20. Kramar, A. et al. Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. Ann. Oncol. 25, 1563-1570 (2014).
21. Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007).
22. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
23. Curtis, C. et al. Supplemental information: the genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
24. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
25. Guedj, M. et al. A refined molecular taxonomy of breast cancer. Oncogene 31, 1196-1206 (2011).
26. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15, 907-913 (2009).
27. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
28. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
29. Langerød, A. et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 9, R30 (2007).
30. Silwal-Pandit, L. et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin. Cancer Res. 20, 3569-3580 (2014).
31. Kancha, R. K. et al. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS ONE 6, e26760 (2011).
32. Perera, D. et al. OncoCis: annotation of cis-regulatory mutations in cancer. Genome Biol. 15, 485 (2014).
33. Staaf, J. et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 12, R25 (2010).
34. Sircoulomb, F. et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 10, 539 (2010).
35. Hicks, J. et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res. 16, 1465-1479 (2006).
36. Yang, L. et al. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 153, 919-929 (2013).
37. Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72, 5454-5462 (2012).
38. McClintock, B. The stability of broken ends of chromosomes in Zea Mays. Genetics 26, 234-282 (1941).
39. Bignell, G. R. et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res. 17, 1296-1303 (2007).
40. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
41. Marotta, M. et al. A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications. Breast Cancer Res. 14, R150 (2012).
42. Zakov, S., Kinsella, M. & Bafna, V. An algorithmic approach for breakagefusion-bridge detection in tumor genomes. Proc. Natl Acad. Sci. USA 110, 5546-5551 (2013).
43. Greenman, C. D., Cooke, S. L., Marshall, J., Stratton, M. R. & Campbell, P. J. Modeling the evolution space of breakage fusion bridge cycles with a stochastic folding process. J. Math. Biol. 72, 47-86 (2015).
44. Sanborn, J. Z. et al. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. Cancer Res. 73, 6036-6045 (2013).
45. Bolstad, B. M. et al. in Bioinformatics and Computational Biology Solutions using R and Bioconductor (eds Gentleman, R., Carey, V., Huber, W., Irizarry, R. A. & Dudoit, S.) 33-47 (Springer, 2005).
46. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003).
47. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315 (2004).
48. Sørlie, T. et al. The importance of gene-centring microarray data. Lancet Oncol. 11, 719-720 (2010).
49. Gendoo, D. M. et al. genefu: Computation of Gene Expression-Based Signatures in Breast Cancer. R package version 2.5.2. Available at http://www.pmgenomics.ca/bhklab/software/genefu (2015).
50. Simon, R. & Lam, A. BRB Array Tools Users Guide. Technical Reports. Biometric Research Branch, National Cancer Institute. Available at http://linus.nci.nih.gov/brb/TechReport (2006).
51. Dunning, M. J., Smith, M. L., Ritchie, M. E. & Tavaré, S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183-2184 (2007).
52. Li, Q., Birkbak, N. J., Gyorffy, B., Szallasi, Z. & Eklund, A. C. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 12, 474 (2011).
53. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRASdriven cancers require TBK1. Nature 462, 108-112 (2009).
54. Staaf, J. et al. Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics 9, 409 (2008).
55. Popova, T. et al. Genome alteration print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol. 10, R128 (2009).
56. Van Loo, P. et al. Analyzing cancer samples with SNP arrays. Methods Mol. Biol. 802, 57-72 (2012).
57. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
58. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
59. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
60. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor. Bioinformatics 26, 2069-2070 (2010).
61. Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455-461 (2014).
62. Benjamini, Y. & Speed, T. P. Summarizing and correcting the GC content bias in high-throughput sequencing. Nucleic Acids Res. 40, e72 (2012).
63. Derrien, T. et al. Fast computation and applications of genome mappability. PLoS ONE 7, e30377 (2012).
64. Zakov, S. & Bafna, V. Reconstructing breakage fusion bridge architectures using noisy copy numbers. J. Comput. Biol. 22, 577-594 (2015).
65. Greenman, C. D. et al. Estimation of rearrangement phylogeny for cancer genomes. Genome Res. 22, 346-361 (2012).
66. Greenacre, M. & Blasius, J. Multiple Correspondence Analysis and Related Methods (Chapman and Hall/CRC, 2006).
67. Thioulouse, J., Chessel, D., Dolédec, S. & Olivier, J. M. ADE-4: a multivariate analysis and graphical display software. Stat. Comput. 7, 75-83 (1997).
68. Benzécri, J. P. Sur le calcul des taux d'inertie dans l'analyse d'un questionnaire. Cahiers de l'Analyse des Données 4, 377-378 (1979).
69. Hoffman, D. L. & De Leeuw, J. Interpreting multiple correspondence analysis as a multidimensional scaling method. Mark, Lett. 3, 259-272 (1992).